ProfileGDS5678 / 1420668_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 78% 76% 75% 77% 78% 78% 77% 76% 76% 76% 77% 77% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2008477
GSM967853U87-EV human glioblastoma xenograft - Control 25.3896678
GSM967854U87-EV human glioblastoma xenograft - Control 35.1711176
GSM967855U87-EV human glioblastoma xenograft - Control 45.0271775
GSM967856U87-EV human glioblastoma xenograft - Control 55.1956277
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2120278
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2378
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1751477
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.1720376
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1248476
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.1388976
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2278577
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1855877
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3536878